<SEC-DOCUMENT>0001791917-26-000005.txt : 20260513
<SEC-HEADER>0001791917-26-000005.hdr.sgml : 20260513
<ACCEPTANCE-DATETIME>20260513110752
ACCESSION NUMBER:		0001791917-26-000005
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260513
DATE AS OF CHANGE:		20260513

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Opus Genetics, Inc.
		CENTRAL INDEX KEY:			0001228627
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				113516358
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-79996
		FILM NUMBER:		26971754

	BUSINESS ADDRESS:	
		STREET 1:		8 DAVIS DRIVE
		STREET 2:		SUITE 220
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		248-681-9815

	MAIL ADDRESS:	
		STREET 1:		8 DAVIS DRIVE
		STREET 2:		SUITE 220
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ocuphire Pharma, Inc.
		DATE OF NAME CHANGE:	20201109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REXAHN PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20050516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORPORATE ROAD SHOW DOT COM INC
		DATE OF NAME CHANGE:	20030423

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOS Fund III, LP
		CENTRAL INDEX KEY:			0001791917
		ORGANIZATION NAME:           	
		EIN:				843385883
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1751 RIVER RUN, SUITE 400
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76107
		BUSINESS PHONE:		817.984.9197

	MAIL ADDRESS:	
		STREET 1:		1751 RIVER RUN, SUITE 400
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76107
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
    <schemaVersion>X0202</schemaVersion>
<headerData>
        <submissionType>SCHEDULE 13G/A</submissionType>
        <previousAccessionNumber>0001104659-25-076281</previousAccessionNumber>
        <filerInfo>
            <filer>
                <filerCredentials>
                    <cik>0001791917</cik>
                    <ccc>XXXXXXXX</ccc>
                </filerCredentials>
            </filer>
            <liveTestFlag>LIVE</liveTestFlag>



        </filerInfo>
    </headerData>
    <formData>
        <coverPageHeader>
            <amendmentNo>2</amendmentNo>
            <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
            <eventDateRequiresFilingThisStatement>05/12/2026</eventDateRequiresFilingThisStatement>
            <issuerInfo>
                <issuerCik>0001228627</issuerCik>
                <issuerName>Opus Genetics, Inc.</issuerName>
                <issuerCusips>
                    <issuerCusipNumber>67577R102</issuerCusipNumber>
                </issuerCusips>
                <issuerPrincipalExecutiveOfficeAddress>
                    <com:street1>8 DAVIS DRIVE, SUITE 220</com:street1>
                    <com:city>DURHAM</com:city>
                    <com:stateOrCountry>NC</com:stateOrCountry>
                    <com:zipCode>27713</com:zipCode>
                </issuerPrincipalExecutiveOfficeAddress>
            </issuerInfo>
            <designateRulesPursuantThisScheduleFiled>
                <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
            </designateRulesPursuantThisScheduleFiled>
        </coverPageHeader>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>AARON G.L. FLETCHER</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>X1</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0</soleVotingPower>
                <sharedVotingPower>3683429</sharedVotingPower>
                <soleDispositivePower>0</soleDispositivePower>
                <sharedDispositivePower>3683429</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3683429</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>4.53</classPercent>
            <typeOfReportingPerson>IN</typeOfReportingPerson>
            <comments>Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Management is a general partner of Bios Equity III. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.</comments>
        </coverPageHeaderReportingPersonDetails>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>BIOS ADVISORS GP, LLC</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>TX</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0</soleVotingPower>
                <sharedVotingPower>3683429</sharedVotingPower>
                <soleDispositivePower>0</soleDispositivePower>
                <sharedDispositivePower>3683429</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3683429</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>4.53</classPercent>
            <typeOfReportingPerson>PN</typeOfReportingPerson>
            <comments>Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Management is a general partner of Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.</comments>
        </coverPageHeaderReportingPersonDetails>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>BIOS CAPITAL MANAGEMENT, LP</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>TX</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0</soleVotingPower>
                <sharedVotingPower>3683429</sharedVotingPower>
                <soleDispositivePower>0</soleDispositivePower>
                <sharedDispositivePower>3683429</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3683429</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>4.53</classPercent>
            <typeOfReportingPerson>PN</typeOfReportingPerson>
            <comments>Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity III and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.</comments>
        </coverPageHeaderReportingPersonDetails>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>BIOS EQUITY PARTNERS III, LP</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>TX</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0</soleVotingPower>
                <sharedVotingPower>3683429</sharedVotingPower>
                <soleDispositivePower>0</soleDispositivePower>
                <sharedDispositivePower>3683429</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3683429</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>4.53</classPercent>
            <typeOfReportingPerson>PN</typeOfReportingPerson>
            <comments>Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds (defined below). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of each of Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT") (collectively, the "Bios III Funds"), and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds.Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026. </comments>
        </coverPageHeaderReportingPersonDetails>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>BIOS FUND III, LP</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>DE</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0</soleVotingPower>
                <sharedVotingPower>430665</sharedVotingPower>
                <soleDispositivePower>0</soleDispositivePower>
                <sharedDispositivePower>430665</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>430665</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>0.53</classPercent>
            <typeOfReportingPerson>PN</typeOfReportingPerson>
            <comments>Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026. </comments>
        </coverPageHeaderReportingPersonDetails>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>BIOS FUND III NT, LP</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>DE</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0</soleVotingPower>
                <sharedVotingPower>450811</sharedVotingPower>
                <soleDispositivePower>0</soleDispositivePower>
                <sharedDispositivePower>450811</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>450811</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>0.55</classPercent>
            <typeOfReportingPerson>PN</typeOfReportingPerson>
            <comments>Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.</comments>
        </coverPageHeaderReportingPersonDetails>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>BIOS FUND III QP, LP</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>DE</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0</soleVotingPower>
                <sharedVotingPower>2801953</sharedVotingPower>
                <soleDispositivePower>0</soleDispositivePower>
                <sharedDispositivePower>2801953</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2801953</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>3.44</classPercent>
            <typeOfReportingPerson>PN</typeOfReportingPerson>
            <comments>Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.</comments>
        </coverPageHeaderReportingPersonDetails>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>CAVU ADVISORS, LLC</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>TX</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0</soleVotingPower>
                <sharedVotingPower>3683429</sharedVotingPower>
                <soleDispositivePower>0</soleDispositivePower>
                <sharedDispositivePower>3683429</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3683429</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>4.53</classPercent>
            <typeOfReportingPerson>PN</typeOfReportingPerson>
            <comments>Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management is a general partner of Bios Equity III. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.  </comments>
        </coverPageHeaderReportingPersonDetails>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>CAVU MANAGEMENT, LP</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>TX</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0</soleVotingPower>
                <sharedVotingPower>3683429</sharedVotingPower>
                <soleDispositivePower>0</soleDispositivePower>
                <sharedDispositivePower>3683429</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3683429</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>4.53</classPercent>
            <typeOfReportingPerson>PN</typeOfReportingPerson>
            <comments>Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity III and, in its capacity as such, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.</comments>
        </coverPageHeaderReportingPersonDetails>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>LESLIE W. KREIS</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>X1</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0</soleVotingPower>
                <sharedVotingPower>3683429</sharedVotingPower>
                <soleDispositivePower>0</soleDispositivePower>
                <sharedDispositivePower>3683429</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3683429</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>4.53</classPercent>
            <typeOfReportingPerson>IN</typeOfReportingPerson>
            <comments>Shared voting and dispositive power consists of 3,683,429 Shares held directly in the aggregate by the Bios III Funds. Bios Equity III is the general partner of each of the Bios III Funds. Cavu Management is a general partner of Bios Equity III. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios III Funds. Percentage based on 81,395,539 Shares outstanding as of May 7, 2026, as reported in the Issuer's Current Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.</comments>
        </coverPageHeaderReportingPersonDetails>
        <items>
            <item1>
                <issuerName>Opus Genetics, Inc.</issuerName>
                <issuerPrincipalExecutiveOfficeAddress>8 DAVIS DRIVE, SUITE 220, DURHAM, NORTH CAROLINA, 27713</issuerPrincipalExecutiveOfficeAddress>
            </item1>
            <item2>
                <filingPersonName>This Schedule 13G is being jointly filed by: Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Equity III, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors, Mr. Kreis, and Dr. Fletcher.</filingPersonName>
                <principalBusinessOfficeOrResidenceAddress>1751 River Run #400 Fort Worth, TX 76107</principalBusinessOfficeOrResidenceAddress>
                <citizenship>Item 2(A) is incorporated herein by reference.</citizenship>
            </item2>
            <item3>
                <notApplicableFlag>Y</notApplicableFlag>
            </item3>
            <item4>
                <amountBeneficiallyOwned>The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.</amountBeneficiallyOwned>
                <classPercent>The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.</classPercent>
                <numberOfSharesPersonHas>
                    <solePowerOrDirectToVote>The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.</solePowerOrDirectToVote>
                    <sharedPowerOrDirectToVote>The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.</sharedPowerOrDirectToVote>
                    <solePowerOrDirectToDispose>The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.</solePowerOrDirectToDispose>
                    <sharedPowerOrDirectToDispose>The information contained in Item 9 of the cover pages of this Schedule 13G is hereby incorporated by reference into this Item 4.</sharedPowerOrDirectToDispose>
                </numberOfSharesPersonHas>
            </item4>
            <item5>
                <notApplicableFlag>N</notApplicableFlag>
                <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
            </item5>
            <item6>
                <notApplicableFlag>Y</notApplicableFlag>
            </item6>
            <item7>
                <notApplicableFlag>Y</notApplicableFlag>
            </item7>
            <item8>
                <notApplicableFlag>Y</notApplicableFlag>
            </item8>
            <item9>
                <notApplicableFlag>N</notApplicableFlag>
                <groupDissolutionNotice>The Related Persons of this Schedule 13G are hereby incorporated by reference into this Item 9.</groupDissolutionNotice>
            </item9>
            <item10>
                <notApplicableFlag>N</notApplicableFlag>
                <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
            </item10>
        </items>
        <signatureInformation>
            <reportingPersonName>AARON G.L. FLETCHER</reportingPersonName>
            <signatureDetails>
                <signature>/s/ John Fucci</signature>
                <title>John Fucci, as Attorney-in-Fact for Aaron G.L. Fletcher</title>
                <date>05/13/2026</date>
            </signatureDetails>
        </signatureInformation>
        <signatureInformation>
            <reportingPersonName>BIOS ADVISORS GP, LLC</reportingPersonName>
            <signatureDetails>
                <signature>/s/ John Fucci</signature>
                <title>John Fucci/Attorney-in-Fact</title>
                <date>05/13/2026</date>
            </signatureDetails>
        </signatureInformation>
        <signatureInformation>
            <reportingPersonName>BIOS CAPITAL MANAGEMENT, LP</reportingPersonName>
            <signatureDetails>
                <signature>/s/ John Fucci</signature>
                <title>John Fucci/Attorney-in-Fact</title>
                <date>05/13/2026</date>
            </signatureDetails>
        </signatureInformation>
        <signatureInformation>
            <reportingPersonName>BIOS EQUITY PARTNERS III, LP</reportingPersonName>
            <signatureDetails>
                <signature>/s/ John Fucci</signature>
                <title>John Fucci/Attorney-in-Fact</title>
                <date>05/13/2026</date>
            </signatureDetails>
        </signatureInformation>
        <signatureInformation>
            <reportingPersonName>BIOS FUND III, LP</reportingPersonName>
            <signatureDetails>
                <signature>/s/ John Fucci</signature>
                <title>John Fucci/Attorney-in-Fact</title>
                <date>05/13/2026</date>
            </signatureDetails>
        </signatureInformation>
        <signatureInformation>
            <reportingPersonName>BIOS FUND III NT, LP</reportingPersonName>
            <signatureDetails>
                <signature>/s/ John Fucci</signature>
                <title>John Fucci/Attorney-in-Fact</title>
                <date>05/13/2026</date>
            </signatureDetails>
        </signatureInformation>
        <signatureInformation>
            <reportingPersonName>BIOS FUND III QP, LP</reportingPersonName>
            <signatureDetails>
                <signature>/s/ John Fucci</signature>
                <title>John Fucci/Attorney-in-Fact</title>
                <date>05/13/2026</date>
            </signatureDetails>
        </signatureInformation>
        <signatureInformation>
            <reportingPersonName>CAVU ADVISORS, LLC</reportingPersonName>
            <signatureDetails>
                <signature>/s/ John Fucci</signature>
                <title>John Fucci/Attorney-in-Fact</title>
                <date>05/13/2026</date>
            </signatureDetails>
        </signatureInformation>
        <signatureInformation>
            <reportingPersonName>CAVU MANAGEMENT, LP</reportingPersonName>
            <signatureDetails>
                <signature>/s/ John Fucci</signature>
                <title>John Fucci/Attorney-in-Fact</title>
                <date>05/13/2026</date>
            </signatureDetails>
        </signatureInformation>
        <signatureInformation>
            <reportingPersonName>LESLIE W. KREIS</reportingPersonName>
            <signatureDetails>
                <signature>/s/ John Fucci</signature>
                <title>John Fucci, as Attorney-in-Fact for Leslie W. Kreis, Jr.</title>
                <date>05/13/2026</date>
            </signatureDetails>
        </signatureInformation>
    </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
